Background: Patients undergoing microvascular decompression are often accompanied with high risk of post-operative nausea and vomiting (PONV). In this study, we compare the antiemetic efficacy of butorphanol or sufentanil combined with dexmedetomidine in patients undergoing microvascular decompression.Methods: Patients undergoing microvascular decompression were randomized into two groups. The primary outcome was the occurrence and severity of PONV during the 72 h after surgery. Secondary outcomes included levels of pain intensity and sedation and consumption of opioids at 1, 2, 6, 12, 24, 48, and 72 h after surgery. We also recorded the intraoperative hemodynamics, consumption of narcotic drugs, operation and anesthesia time, estimated blood loss, infusion volume and urine output, requirements of rescue antiemetics or analgesics, the satisfaction scores of patients and surgeons, complications, and length of stay.Results: The overall incidence rates of nausea and vomiting during the 72 h after surgery were significantly reduced in group DB (76.00 and 44.00% in group DS vs. 54.17% and 22.92% in group DB, P < 0.05). Patients in group DB had a lower incidence of nausea than those in group DS at intervals of 1-6 and 6-24 h (P < 0.05). However, patients in group DB had a lower incidence of vomiting than those in group DS only at intervals of 1-6 h (P < 0.05). Similarly, the number of patients requiring rescue antiemetics was also significantly reduced in group DB compared with that in group DS at intervals of 1-6 h (P < 0.05). The number of patients experiencing moderate to severe PONV was comparable between the two groups during 72 h after surgery (P > 0.05). The consumption of opioid morphine equivalent was significantly reduced in group DB (P < 0.05). Compared with those in group DS, the satisfaction scores of both patients and surgeons were significantly increased in group DB (P < 0.05). Xu et al.Butorphanol or Sufentanil for PONV Conclusion: Butorphanol combined with dexmedetomidine could reduce early PONV and the number of patients requiring rescue antiemetics, especially at intervals of 1-6 h, while the satisfaction scores of both patients and surgeons were significantly increased.

Background Anxiety and uncooperation are common among pediatric patients during the preoperative preparation, which requires adequate and appropriate analgesia and sedation. Methods We performed a prospective, randomized, double-blind, controlled clinical trial involving 1–6-year-old pediatric patients scheduled for elective tonsillectomy or adenoidectomy between December 2020 and May 2021. Patients were randomly assigned to control (group C), esketamine 1 mg.kg− 1 (group EK1), or esketamine 2 mg.kg− 1 (group EK2) group. Venipuncture analgesia, cooperation, and sedation, as well as satisfaction upon parent–child separation, cooperation, sedation, and adverse events, were compared among the three groups. Dynamic changes in the sedation score and vital signs were monitored. Results A total of 88 pediatric patients were analyzed, with 29, 29, and 30 patients in groups C, EK1, and EK2, respectively. Compared with group C, groups EK1 and EK2 both had better analgesia during venipuncture (P < 0.001). In addition, better cooperation and sedation was noticed in groups EK1 and EK2 during parent–child separation and venipuncture than in group C. Compared with the baseline, the mean respiratory rate had a significant decrease from 25.6 ± 0.3 to 24.6 ± 0.4 breaths/min at 30 min after the esketamine administration in group EK2, although it was still within normal limits (P = 0.030). There were no significant differences in adverse events among three groups. Conclusions Preoperative oral administration of 1 or 2 mg.kg− 1 esketamine in pediatric patients could achieve effective analgesia and sedation. Oral medication of 2 mg.kg− 1 esketamine had more pronounced effects. Trial registration : This clinical trial was registered at the Chinese Clinical Trial Registry (ChiCTR2000040739) on 08/12/2020.

Background Perioperative medicines can affect the body's immune response, according to data reported a variety of anesthetic drugs can directly or indirectly affect the immune response, this study aims to preliminarily common muscle relaxant presence of anti-inflammatory effects. Methods To collect peripheral blood of healthy adults, and designed the following treatment groups: [A] blank group; [B] static and unstimulated drug groups: the group contained two concentrations of both pipecuronium and vecuronium respectively (0.5/0.1g•ml-1); [L] simple lipopolysaccharide (LPS) group; [C] under stimulated drug groups: two concentrations (0.5/0.1g•ml-1) muscle relaxants were added with lipopolysaccharide in each group. Detection of average fluorescence emphasized expression of CD11b on neutrophils by flow cytometry. Results Compared with the blank control group [A], the expression of CD11b in each group was significantly increased in the LPS group [L] and the stimulus drug groups [C](p<0.001). Compared with the blank control group [A], low concentration of vecuronium and pipecuronium could inhibit the expression of CD11b on the surface of neutrophils (vecuronium 95% CI: 20.47 to 37.28, p<0.001),(pipecuronium 95% CI: 18.63 to 50.22, p<0.001). High concentrations of vecuronium and pipecuronium to CD11b expression differences had no statistical significance (p > 0.05). Conclusions The concentration of vecuronium and pipecuronium that approximates clinical maintenance dose has effect of inhibiting the CD11b expression of human neutrophil in venous blood in vitro. The results of this study can provide the reference for muscle relaxant immunological research and clinical rational use .